Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Life Science Investing
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities Life Science Investing
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors Life Science Investing
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Life Science Investing
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 Life Science Investing
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency at the American Thoracic Society 2026 International Conference Life Science Investing
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides Life Science Investing
NRx Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
